NT-proBNP和CysC在慢性心肾综合征早期诊断和预后评价中的研究

Study of NT-proBNP and CysC in Early Diagnosis and Prognosis of Chronic Cardiopulmonary Syndrome

目的在慢性心肾综合征(CRS)早期诊断中检测N末端B型氨基端利钠肽原(NT-proBNP)和胱抑素C(CysC)及对患者预后效果的评价价值。方法随机抽取该院2016年5月—2017年5月收治的200例性心力衰竭(CHF)患者展开研究,将其中肾小球滤过率(GFR)低于60 m L/min的100例作为A组;其余GFR超过60 m L/min的100例作为B组,对比两组NT-proBNP、CysC、血清肌酐(Scr)检测结果。结果 (1)A组NT-proBNP水平、CysC水平、Scr水平依次是(2.39±0.68)μg/L、(1.75±0.60)mg/L、(388.65±63.23)μmol/L,显著高于B组的(0.82±0.12)μg/L、(0.98±0.34)mg/L、(76.22±10.31)μmol/L,比较差异有统计学意义(P<0.05)。(2)A组Ⅱ级患者的NT-proBNP、CysC、Scr水平低于Ⅲ级(P<0.05),Ⅲ级低于IV级(P<0.05)。I期慢性CRS患者的NT-proBNP水平、CysC水平、Scr水平低于Ⅱ期(P<0.05);Ⅱ期低于Ⅲ期;Ⅲ期低于IV期(P<0.05)。结论检测慢性CRS患者的NT-proBNP、CysC可以明确其病程程度,同时又能对预后效果给予有效评估。

Objective This paper tries to evaluate the value of N-terminal pro-N-terminal pro-brain natriuretic peptide(NT-proBNP)and cystatin C(CysC)in the early diagnosis of chronic heart-kidney syndrome(CRS)and to evaluate their prognostic value.Methods A total of 200 patients with congestive heart failure(CHF)admitted to this hospital from May 2016 to May 2017 were random selected in this study.100 patients with glomerular filtration rate(GFR)less than 60 mL/min were selected as group A;The remaining 100 cases of GFR exceeded 60 mL/min as group B,and compared the results of NT-pro BNP,CysC and serum creatinine(Scr).Results①The levels of NT-proBNP,CysC and Scr in group A were(2.39±0.68)μg/L,(1.75±0.60)mg/L and(388.65±63.23)μmol/L,significantly higher than that of group B of respectively(0.82±0.12)μg/L,(0.98±0.34)mg/L,(76.22±10.31)μmol/L,with significant difference(P<0.05).②NT-proBNP,CysC and Scr in group A patients with grade II were lower than grade III(P<0.05),grade III was lower than grade IV(P<0.05).The level of NT-proBNP,CysC and Scr in stage I patients with chronic CRS were lower than those in stage II(P<0.05);stage II was lower than stage III;stage III was lower than stage IV(P<0.05).Conclusion The detection of NT-proBNP and CysC in patients with chronic CRS can confirm the course of the disease and at the same time can effectively evaluate the prognosis.